Last reviewed · How we verify
AUVA Traumazentrum Vienna Site UKH Meidling — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aarhus University Hospital · 1 shared drug class
- Amgen · 1 shared drug class
- Axsome Therapeutics, Inc. · 1 shared drug class
- Chinese Society of Lung Cancer · 1 shared drug class
- Chinese University of Hong Kong · 1 shared drug class
- Cttq · 1 shared drug class
- Daiichi Sankyo Co., Ltd. · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for AUVA Traumazentrum Vienna Site UKH Meidling:
- AUVA Traumazentrum Vienna Site UKH Meidling pipeline updates — RSS
- AUVA Traumazentrum Vienna Site UKH Meidling pipeline updates — Atom
- AUVA Traumazentrum Vienna Site UKH Meidling pipeline updates — JSON
Cite this brief
Drug Landscape (2026). AUVA Traumazentrum Vienna Site UKH Meidling — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/auva-traumazentrum-vienna-site-ukh-meidling. Accessed 2026-05-18.